Drug intelligence / Profile preview

miR433-3p tough decoy inhibitor

Development stage
Preclinical
Lead developer
University of Connecticut
Modality
Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

The miR433-3p tough decoy inhibitor (miR-433-3p TuD) is a preclinical research tool designed to competitively inhibit and sequester the microRNA miR-433-3p. Custom-synthesized as a synthetic RNA construct with tandem miR-433-3p binding sites, the decoy features a secondary structure that resists degradation. It is typically delivered via lentiviral or transgenic expression (such as knock-in at the Rosa26 locus) to study the role of miR-433-3p in bone formation, osteoblast differentiation, and growth plate dynamics. By sequestering miR-433-3p, the decoy prevents the microRNA from binding and suppressing its endogenous mRNA targets, which include Runx2, Hsd11b1, Sost, Dkk1, Hdac6, and Hif1a. In animal models, suppression of miR-433-3p activity in the osteoblast or osteochondral lineage increases trabecular bone volume, enhances bone formation, and blunts glucocorticoid-induced bone loss, though it can also disrupt growth plate development.

Other names
miR-433 TuDmiR433 TuDmiR 433 TuDmiR-433-3p TuDmiR433-3p TuDmiR 433-3p TuDmiR-433-3p tough decoymiR433-3p tough decoymiR 433-3p tough decoymiR-433-3p tough decoy inhibitormiR433-3p tough decoy inhibitormiR 433-3p tough decoy inhibitormiR433-TuDmiR-433-TuDmiR 433-TuD

Beyond the preview

Go deeper on miR433-3p tough decoy inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR433-3p tough decoy inhibitor.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call